Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Caribou Biosciences Inc shares valued at $24,651 were purchased by Ryali Sriram on Jan 29 ’25. At $1.42 per share, Ryali Sriram acquired 17,360 shares. The insider’s holdings grew to 17,360 shares worth approximately $22741.600000000002 following the completion of this transaction.
As published in a research note from Evercore ISI on June 03, 2024, Caribou Biosciences Inc [CRBU] has been rated down from an Outperform to an In-line and the price target has been revised to $3 from $13. Analysts at Cantor Fitzgerald started covering the stock with ‘”a Neutral”‘ outlook in a report released in early November. As of October 31, 2023, Evercore ISI has initiated its “an Outperform” rating for CRBU. Earlier on July 11, 2023, Truist initiated its rating. Their recommendation was “a Buy” for CRBU stock.
Analyzing CRBU Stock Performance
During the last five days, there has been a drop of approximately -13.82%. Over the course of the year, Caribou Biosciences Inc shares have dropped approximately -17.61%. Shares of the company reached a 52-week high of $2.0400 on 01/07/25 and a 52-week low of $1.3000 on 01/30/25. A 50-day SMA is recorded $1.8043, while a 200-day SMA reached $2.2281. Nevertheless, trading volume fell to 1.65 million shares from 1.3 million shares the previous day.
Support And Resistance Levels for Caribou Biosciences Inc (CRBU)
According to the 24-hour chart, there is a support level at 1.2833, which, if violated, would cause prices to drop to 1.2567. In the upper region, resistance lies at 1.3533. The next price resistance is at 1.3967. RSI (Relative Strength Index) is 24.60 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1493, which suggests the price will decrease in the coming days. Percent R is at 97.73%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
